Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 12

1.

Cost Effectiveness of Influenza Vaccine Choices in Children Aged 2-8 Years in the U.S.

Smith KJ, Raviotta JM, DePasse JV, Brown ST, Shim E, Patricia Nowalk M, Zimmerman RK.

Am J Prev Med. 2016 May;50(5):600-8. doi: 10.1016/j.amepre.2015.12.010. Epub 2016 Feb 8.

PMID:
26868283
2.

Aging, cytomegalovirus (CMV) and influenza vaccine responses.

Frasca D, Blomberg BB.

Hum Vaccin Immunother. 2016 Mar 3;12(3):682-90. doi: 10.1080/21645515.2015.1105413.

3.

Net Costs Due to Seasonal Influenza Vaccination--United States, 2005-2009.

Carias C, Reed C, Kim IK, Foppa IM, Biggerstaff M, Meltzer MI, Finelli L, Swerdlow DL.

PLoS One. 2015 Jul 31;10(7):e0132922. doi: 10.1371/journal.pone.0132922. eCollection 2015.

4.

High TNF-α levels in resting B cells negatively correlate with their response.

Frasca D, Diaz A, Romero M, Landin AM, Blomberg BB.

Exp Gerontol. 2014 Jun;54:116-22. doi: 10.1016/j.exger.2014.01.004. Epub 2014 Jan 15.

5.

FRED (a Framework for Reconstructing Epidemic Dynamics): an open-source software system for modeling infectious diseases and control strategies using census-based populations.

Grefenstette JJ, Brown ST, Rosenfeld R, DePasse J, Stone NT, Cooley PC, Wheaton WD, Fyshe A, Galloway DD, Sriram A, Guclu H, Abraham T, Burke DS.

BMC Public Health. 2013 Oct 8;13:940. doi: 10.1186/1471-2458-13-940.

6.

Optimal targeting of seasonal influenza vaccination toward younger ages is robust to parameter uncertainty.

Ndeffo Mbah ML, Medlock J, Meyers LA, Galvani AP, Townsend JP.

Vaccine. 2013 Jun 26;31(30):3079-89. doi: 10.1016/j.vaccine.2013.04.052. Epub 2013 May 16.

7.

Effects of age on H1N1-specific serum IgG1 and IgG3 levels evaluated during the 2011-2012 influenza vaccine season.

Frasca D, Diaz A, Romero M, Mendez NV, Landin AM, Blomberg BB.

Immun Ageing. 2013 Apr 22;10(1):14. doi: 10.1186/1742-4933-10-14.

8.

Vaccine allocation in a declining epidemic.

Goldstein E, Wallinga J, Lipsitch M.

J R Soc Interface. 2012 Nov 7;9(76):2798-803. Epub 2012 Jul 6.

9.

Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine.

Smith KJ, Wateska AR, Nowalk MP, Raymund M, Nuorti JP, Zimmerman RK.

JAMA. 2012 Feb 22;307(8):804-12. doi: 10.1001/jama.2012.169.

10.

Serological memory and long-term protection to novel H1N1 influenza virus after skin vaccination.

Koutsonanos DG, del Pilar Martin M, Zarnitsyn VG, Jacob J, Prausnitz MR, Compans RW, Skountzou I.

J Infect Dis. 2011 Aug 15;204(4):582-91. doi: 10.1093/infdis/jir094. Epub 2011 Jun 17.

11.

The benefits to all of ensuring equal and timely access to influenza vaccines in poor communities.

Lee BY, Brown ST, Bailey RR, Zimmerman RK, Potter MA, McGlone SM, Cooley PC, Grefenstette JJ, Zimmer SM, Wheaton WD, Quinn SC, Voorhees RE, Burke DS.

Health Aff (Millwood). 2011 Jun;30(6):1141-50. doi: 10.1377/hlthaff.2010.0778.

12.

Improving the evidence base for decision making during a pandemic: the example of 2009 influenza A/H1N1.

Lipsitch M, Finelli L, Heffernan RT, Leung GM, Redd SC; 2009 H1n1 Surveillance Group..

Biosecur Bioterror. 2011 Jun;9(2):89-115. doi: 10.1089/bsp.2011.0007.

Supplemental Content

Support Center